Category - News

Markets

Analysts raise Forty Seven price targets on 5F9 data

Analysts for H.C. Wainwright and BTIG raised their price targets for Forty Seven (NASDAQ:FTSV) after the company updated results from its ongoing Phase 1b clinical study of magrolimab (5F9) in combination with...

December 10, 2019

Developments

Hepion to present CRV431 clinical and scientific updates at HEP DART 2019 meeting

Hepion Pharmaceuticals (NASDAQ:HEPA) is slated to present two posters at the HEP DART 2019, frontiers in drug development for hepatology, including viral hepatitis, NASH and co-infections meeting. The presentations...

December 9, 2019

Developments

ObsEva reports positive results from Phase 3 study of linzagolix

ObsEva’s (NASDAQ:OBSV) Phase 3 trial of linzagolix for the treatment of heavy menstrual bleeding (HMB) due to uterine fibroids met its primary and secondary endpoints. The U.S. trial enrolled 535 women to evaluate the...

December 9, 2019

Developments

FDA removes hold on Abeona’s pivotal gene therapy trial

The FDA removed its clinical hold on Abeona Therapeutics’ (NASDAQ:ABEO) Phase 3 clinical trial evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). The hold was removed following...

December 9, 2019

Markets

SVB Leerink starts 89bio at OP; PT $55

SVC Leerink initiated coverage of 89bio (NASDAQ:ETNB) with an “outperform” rating and $55 price target. The stock closed at $28.60 on Dec. 6. 89bio is developing a fibroblast growth factor (FGF) 21 analog, BIO89-100, in...

December 9, 2019

Markets

WB ups Diplomat Pharmacy to market perform

William Blair upgraded Diplomat Pharmacy (NYSE:DPLO) to “market perform” from “underperform” after UnitedHealth Group’s (NYSE:UNH) OptumRx agreed to acquire Diplomat for $4 a share. Shares of Diplomat were quoted at $3...

December 9, 2019

Developments

Musculoskeletal company Trainer Rx changes name to RecoveryOne

Closely-held RecoveryOne, formerly Trainer Rx, which is focused on enabling patient recovery from musculoskeletal (MSK) conditions, is raising $12-million in a round led by Cigna Ventures. The company says the financing...

December 9, 2019

Developments

Positive buzz on new prostate disease treatment, TULSA-PRO, coming out of RSNA annual meeting

According to a number of trade media reports, Profound Medical’s (NASDAQ:PROF; TSX:PRN) recently 510(k)-cleared TULSA-PRO system received high marks at the Radiology Society of North America (RSNA) annual meeting. TULSA...

December 6, 2019

Markets

HCW starts Puma Biotechnology at buy; PT $15

H.C. Wainwright launched coverage of Puma Biotechnology (NASDAQ:PBYI) with a “buy” rating and $15 price target. The stock closed at $7.44 on Dec. 5. Puma has a marketed drug called Nerlynx, which was approved by the FDA...

December 6, 2019

Developments

Omeros reports positive data from pivotal narsoplimab trial

Omeros (NASDAQ:OMER) reported positive data from its pivotal clinical trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). HSCT-TMA occurs when...

December 5, 2019

Category - News

Analysts raise Forty Seven price targets on 5F9 data

Hepion to present CRV431 clinical and scientific updates at HEP DART 2019 meeting

ObsEva reports positive results from Phase 3 study of linzagolix

FDA removes hold on Abeona’s pivotal gene therapy trial

SVB Leerink starts 89bio at OP; PT $55

WB ups Diplomat Pharmacy to market perform

Musculoskeletal company Trainer Rx changes name to RecoveryOne

Positive buzz on new prostate disease treatment, TULSA-PRO, coming out of RSNA annual meeting

HCW starts Puma Biotechnology at buy; PT $15

Omeros reports positive data from pivotal narsoplimab trial

General

More